The pro-tumoral effect of M1-like TAMs was reverted by the administration of the p65 inhibitor, JSH-23, underlying the controversial role of NF-κB in M1 TAMs in HCC progression [101]. The gene discussed is NFKB1; the disease is hepatocellular carcinoma.